{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:41:34Z","timestamp":1759995694891,"version":"build-2065373602"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11882-025-01224-7","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:48:31Z","timestamp":1759988911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using Biologics in the Prevention of Anaphylaxis"],"prefix":"10.1007","volume":"25","author":[{"given":"Daniel","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amika K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Schworer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyinye I.","family":"Iweala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mildred","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"1224_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100472","volume":"13","author":"V Cardona","year":"2020","unstructured":"Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13:100472.","journal-title":"World Allergy Organ J"},{"key":"1224_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2500\/jfa.2020.2.200001","volume":"2","author":"M Hearrell","year":"2020","unstructured":"Hearrell M, Anagnostou A. Diagnosis and management of anaphylaxis. J Food Allergy. 2020;2:64\u20138.","journal-title":"J Food Allergy"},{"key":"1224_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jama.2023.26857","volume":"331","author":"EGA Iglesia","year":"2024","unstructured":"Iglesia EGA, Kwan M, Virkud YV, Iweala OI. Management of food allergies and food-related anaphylaxis. JAMA. 2024;331:510\u201321.","journal-title":"JAMA"},{"key":"1224_CR4","doi-asserted-by":"crossref","unstructured":"Esteban V, Skrabski F, Perales-Chorda C, Puente-Crespo Y, Mu\u00f1oz-Cano R, Cardona V et al. Perspectives in the molecular mechanisms underlying anaphylaxis. J Investig Allergol Clin Immunol. 2025;35(4):251\u2013266.","DOI":"10.18176\/jiaci.1080"},{"key":"1224_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/imr.13380","volume":"328","author":"A Eggel","year":"2024","unstructured":"Eggel A, Pennington LF, Jardetzky TS. Therapeutic monoclonal antibodies in allergy: targeting IgE, cytokine, and alarmin pathways. Immunol Rev. 2024;328:387\u2013411.","journal-title":"Immunol Rev"},{"key":"1224_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaci.2003.11.033","volume":"113","author":"K Bohlke","year":"2004","unstructured":"Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol. 2004;113:536\u201342.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/all.12272","volume":"68","author":"SS Panesar","year":"2013","unstructured":"Panesar SS, Javad S, de Silva D, Nwaru BI, Hickstein L, Muraro A, et al. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy. 2013;68:1353\u201361.","journal-title":"Allergy"},{"key":"1224_CR8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jaci.2008.09.043","volume":"122","author":"WW Decker","year":"2008","unstructured":"Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL, Weaver A, et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester epidemiology project. J Allergy Clin Immunol. 2008;122:1161\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/cei.13665","volume":"206","author":"C Martinez","year":"2021","unstructured":"Martinez C, Wallenhorst C, van Nunen S. Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study. Clin Exp Immunol. 2021;206:384\u201394.","journal-title":"Clin Exp Immunol"},{"key":"1224_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1365-2125.2011.03913.x","volume":"71","author":"L Nel","year":"2011","unstructured":"Nel L, Eren E. Peri-operative anaphylaxis. Br J Clin Pharmacol. 2011;71:647\u201358.","journal-title":"Br J Clin Pharmacol"},{"key":"1224_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.anai.2016.10.031","volume":"118","author":"DBK Golden","year":"2017","unstructured":"Golden DBK, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118:28\u201354.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jaci.2022.01.009","volume":"149","author":"DI Bernstein","year":"2022","unstructured":"Bernstein DI, Epstein TG. Managing risk of anaphylaxis in patients receiving allergen immunotherapy: assessing benefit versus risk. J Allergy Clin Immunol. 2022;149:884\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR13","doi-asserted-by":"publisher","unstructured":"G\u00fclen T. A puzzling mast cell trilogy: anaphylaxis, MCAS, and mastocytosis. Diagnostics (Basel). 2023;13(21):3307. https:\/\/doi.org\/10.3390\/diagnostics13213307","DOI":"10.3390\/diagnostics13213307"},{"key":"1224_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s40521-017-0136-2","volume":"4","author":"BI Nwaru","year":"2017","unstructured":"Nwaru BI, Dhami S, Sheikh A. Idiopathic anaphylaxis. Curr Treat Options Allergy. 2017;4:312\u20139.","journal-title":"Curr Treat Options Allergy"},{"key":"1224_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/all.15032","volume":"77","author":"A Muraro","year":"2022","unstructured":"Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy. 2022;77:357\u201377.","journal-title":"Allergy"},{"key":"1224_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.emc.2021.08.004","volume":"40","author":"K McHugh","year":"2022","unstructured":"McHugh K, Repanshek Z. Anaphylaxis: Emergency department treatment. Emerg Med Clin North Am. 2022;40:19\u201332.","journal-title":"Emerg Med Clin North Am"},{"key":"1224_CR17","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.jaci.2013.10.029","volume":"133","author":"L Ma","year":"2014","unstructured":"Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:1075\u201383.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cea.14249","volume":"53","author":"RC Knibb","year":"2023","unstructured":"Knibb RC, Huissoon AP, Baretto R, Ekbote A, Onyango-Odera S, Screti C, et al. The impact of anaphylaxis on the quality of life and mental health of adults. Clin Exp Allergy. 2023;53:121\u20135.","journal-title":"Clin Exp Allergy"},{"key":"1224_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11882-016-0614-9","volume":"16","author":"CM Warren","year":"2016","unstructured":"Warren CM, Otto AK, Walkner MM, Gupta RS. Quality of life among food allergic patients and their caregivers. Curr Allergy Asthma Rep. 2016;16:38.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1224_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-023-00824-0","volume":"19","author":"LS Gardner","year":"2023","unstructured":"Gardner LS, Tan Z, Brown D, Gillis D, Scott JG, Prentice R. Mental health problems associated with idiopathic anaphylaxis. Allergy Asthma Clin Immunol. 2023;19:84.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1224_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4168\/aair.2020.12.3.496","volume":"12","author":"Y Lee","year":"2020","unstructured":"Lee Y, Chang HY, Kim SH, Yang MS, Koh YI, Kang HR, et al. A prospective observation of psychological distress in patients with anaphylaxis. Allergy Asthma Immunol Res. 2020;12:496\u2013506.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1224_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4168\/aair.2022.14.6.742","volume":"14","author":"K Jeong","year":"2022","unstructured":"Jeong K, Kim J, Chang HY, Song TW, Kim JH, Shin M, et al. Maternal posttraumatic stress symptoms and psychological burden in mothers of Korean children with anaphylaxis. Allergy Asthma Immunol Res. 2022;14:742\u201351.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1224_CR23","unstructured":"Definition of biologic agent [Internet]. [cited 2025 Jul 27]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/biologic-agent"},{"key":"1224_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","volume":"17","author":"HM Shepard","year":"2017","unstructured":"Shepard HM, Phillips GL, Thanos D, Feldmann C. Developments in therapy with monoclonal antibodies and related proteins. Clin Med. 2017;17:220\u201332.","journal-title":"Clin Med"},{"key":"1224_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","volume":"12","author":"NAPS Buss","year":"2012","unstructured":"Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12:615\u201322.","journal-title":"Curr Opin Pharmacol"},{"key":"1224_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1572283","volume":"16","author":"SK Hund","year":"2025","unstructured":"Hund SK, Sampath V, Zhou X, Thai B, Desai K, Nadeau KC. Scientific developments in understanding food allergy prevention, diagnosis, and treatment. Front Immunol. 2025;16:1572283.","journal-title":"Front Immunol"},{"key":"1224_CR27","doi-asserted-by":"publisher","first-page":"e075253","DOI":"10.1136\/bmjopen-2023-075253","volume":"14","author":"A Honda","year":"2024","unstructured":"Honda A, Okada Y, Matsushita T, Hasegawa T, Ota E, Noma H, et al. Efficacy of biological agents combined with oral immunotherapy (OIT) for food allergy: a protocol for a systematic review and meta-analysis. BMJ Open. 2024;14:e075253.","journal-title":"BMJ Open"},{"key":"1224_CR28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2217\/imt-2020-0123","volume":"12","author":"SA Schworer","year":"2020","unstructured":"Schworer SA, Kim EH. Sublingual immunotherapy for food allergy and its future directions. Immunotherapy. 2020;12:921\u201331.","journal-title":"Immunotherapy"},{"key":"1224_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","volume":"130","author":"JH Savage","year":"2012","unstructured":"Savage JH, Courneya J-P, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130:1123\u2013e11292.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR30","doi-asserted-by":"crossref","unstructured":"Sampson HA, Leung DYM, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309\u2013e101.","DOI":"10.1016\/j.jaci.2011.01.051"},{"key":"1224_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","volume":"3","author":"S Andorf","year":"2018","unstructured":"Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3:85\u201394.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1224_CR32","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/all.16314","volume":"80","author":"S Arasi","year":"2025","unstructured":"Arasi S, Cafarotti A, Galletta F, Panetta V, Riccardi C, Calandrelli V, et al. Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: an observational study. Allergy. 2025;80:1074\u201385.","journal-title":"Allergy"},{"issue":"4","key":"1224_CR33","first-page":"1134","volume":"11","author":"T Zuberbier","year":"2023","unstructured":"Zuberbier T, Wood RA, Bindslev-Jensen C, Fiocchi A, Chinthrajah RS, Worm M, et al. Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(4):1134\u201346.","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"1224_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2500\/aap.2010.31.3304","volume":"31","author":"A Rafi","year":"2010","unstructured":"Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW, Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc. 2010;31:76\u201383.","journal-title":"Allergy Asthma Proc"},{"key":"1224_CR35","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.jaci.2008.12.114","volume":"123","author":"AM Plaza-Martin","year":"2009","unstructured":"Plaza-Martin AM, Giner-Mu\u00f1oz MT, Dominguez-Sanchez O, Piquer-Gibert M, Martin-Mateos MA. Omalizumab and the induction of tolerance to cow\u2019s milk proteins in children at high risk of anaphylaxis. J Allergy Clin Immunol. 2009;123:S26\u201326.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR36","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2312382","volume":"390","author":"RA Wood","year":"2024","unstructured":"Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, et al. Omalizumab for the treatment of multiple food allergies. N Engl J Med. 2024;390:889\u201399.","journal-title":"N Engl J Med"},{"key":"1224_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101048","volume":"18","author":"A Alexiou","year":"2025","unstructured":"Alexiou A, Carreras-K\u00e0tcheff S, Hartmann K, Treudler R, Tassinari P, Cardona V, et al. Efficacy of omalizumab in food allergic adults - a retrospective analysis. World Allergy Organ J. 2025;18:101048.","journal-title":"World Allergy Organ J"},{"key":"1224_CR38","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1111\/all.14308","volume":"75","author":"P Guntern","year":"2020","unstructured":"Guntern P, Eggel A. Past, present, and future of anti-IgE biologics. Allergy. 2020;75:2491\u2013502.","journal-title":"Allergy"},{"key":"1224_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100690","volume":"15","author":"RA Wood","year":"2022","unstructured":"Wood RA, Chinthrajah RS, Eggel A, Bottoli I, Gautier A, Woisetschlaeger M, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J. 2022;15:100690.","journal-title":"World Allergy Organ J"},{"key":"1224_CR40","unstructured":"Efficacy. and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy [Internet]. [cited 2025 Jul 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04984876"},{"key":"1224_CR41","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med"},{"key":"1224_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/all.16404","volume":"80","author":"SB Sindher","year":"2025","unstructured":"Sindher SB, Nadeau KC, Chinthrajah RS, Leflein JG, B\u00e9gin P, Ohayon JA, et al. Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study. Allergy. 2025;80:227\u201337.","journal-title":"Allergy"},{"key":"1224_CR43","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/all.16420","volume":"80","author":"RS Chinthrajah","year":"2025","unstructured":"Chinthrajah RS, Sindher SB, Nadeau KC, Leflein JG, Spergel JM, Petroni DH, et al. Dupilumab as an adjunct to oral immunotherapy in pediatric patients with peanut allergy. Allergy. 2025;80:827\u201342.","journal-title":"Allergy"},{"key":"1224_CR44","unstructured":"Dupilumab. and Milk OIT for the Treatment of Cow\u2019s Milk Allergy [Internet]. [cited 2025 Jul 12]. Available from: https:\/\/clinicaltrials.stanford.edu\/trials\/d\/NCT04148352.html"},{"key":"1224_CR45","unstructured":"Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE). [Internet]. [cited 2025 Jul 12]. Available from: https:\/\/stanfordhealthcare.org\/trials\/c\/NCT03679676.html"},{"key":"1224_CR46","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.2147\/JIR.S471963","volume":"17","author":"G Zhao","year":"2024","unstructured":"Zhao G, Wang Z, Zhang J, Lin Y, Zhou T, Liu K, et al. Preclinical development of SHR-1819, a potent humanized IL-4R\u03b1 antibody for treating type 2 inflammatory diseases. J Inflamm Res. 2024;17:6375\u201388.","journal-title":"J Inflamm Res"},{"key":"1224_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2500\/jfa.2020.2.200004","volume":"2","author":"M Chen","year":"2020","unstructured":"Chen M, Zhang W, Lee L, Saxena J, Sindher S, Chinthrajah RS, et al. Biologic therapy for food allergy. Journal of Food Allergy. 2020;2:86\u201390.","journal-title":"Journal of Food Allergy"},{"key":"1224_CR48","doi-asserted-by":"publisher","unstructured":"Ding W, Zou G-L, Zhang W, Lai X-N, Chen H-W, Xiong L-X. Interleukin-33: its emerging role in allergic diseases. Molecules. 2018;23(7):1665. https:\/\/doi.org\/10.3390\/molecules23071665","DOI":"10.3390\/molecules23071665"},{"key":"1224_CR49","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.jaci.2016.03.056","volume":"138","author":"C Galand","year":"2016","unstructured":"Galand C, Leyva-Castillo JM, Yoon J, Han A, Lee MS, McKenzie ANJ, et al. IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells. J Allergy Clin Immunol. 2016;138:1356\u201366.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR50","doi-asserted-by":"publisher","unstructured":"Chinthrajah S, Cao S, Liu C, Lyu S-C, Sindher SB, Long A, et al. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight. 2019;4(22):e131347. https:\/\/doi.org\/10.1172\/jci.insight.131347","DOI":"10.1172\/jci.insight.131347"},{"key":"1224_CR51","doi-asserted-by":"publisher","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","volume":"13","author":"E England","year":"2023","unstructured":"England E, Rees DG, Scott IC, Carmen S, Chan DTY, Chaillan Huntington CE, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023;13:9825.","journal-title":"Sci Rep"},{"key":"1224_CR52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaci.2017.02.046","volume":"141","author":"MV Khodoun","year":"2018","unstructured":"Khodoun MV, Tomar S, Tocker JE, Wang YH, Finkelman FD. Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33. J Allergy Clin Immunol. 2018;141:171\u2013e1791.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/13543784.2025.2453162","volume":"34","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zheng W, Peng R, Wu D, Hu Y, Sun T, et al. First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers. Expert Opin Investig Drugs. 2025;34:81\u20137.","journal-title":"Expert Opin Investig Drugs"},{"key":"1224_CR54","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1358\/dot.2022.58.12.3449205","volume":"58","author":"S Nolasco","year":"2022","unstructured":"Nolasco S, Pelaia C, Scioscia G, Campisi R, Crimi C. Tezepelumab for asthma. Drugs Today (Barc). 2022;58:591\u2013603.","journal-title":"Drugs Today (Barc)"},{"key":"1224_CR55","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/all.16590","volume":"80","author":"J Gates","year":"2025","unstructured":"Gates J, Haris F, Cefaloni F, Khooshemehri P, Green L, Fernandes M, et al. Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma. Allergy. 2025;80:1669\u201376.","journal-title":"Allergy"},{"key":"1224_CR56","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","volume":"127","author":"L Cox","year":"2011","unstructured":"Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1\u201355.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR57","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jor.1100050303","volume":"5","author":"A Schultz","year":"1987","unstructured":"Schultz A, Cromwell R, Warwick D, Andersson G. Lumbar trunk muscle use in standing isometric heavy exertions. J Orthop Res. 1987;5:320\u20139.","journal-title":"J Orthop Res"},{"key":"1224_CR58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2500\/aap.2020.41.200001","volume":"41","author":"DI Bernstein","year":"2020","unstructured":"Bernstein DI, Epstein TEG. Safety of allergen immunotherapy in North America from 2008\u20132017: lessons learned from the ACAAI\/AAAAI national surveillance study of adverse reactions to allergen immunotherapy. Allergy Asthma Proc. 2020;41:108\u201311.","journal-title":"Allergy Asthma Proc"},{"key":"1224_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.anai.2021.03.011","volume":"127","author":"TG Epstein","year":"2021","unstructured":"Epstein TG, Murphy-Berendts K, Liss GM, Bernstein DI. Risk factors for fatal and nonfatal reactions to immunotherapy (2008\u20132018): postinjection monitoring and severe asthma. Ann Allergy Asthma Immunol. 2021;127:64\u2013e691.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-017-0160-0","volume":"7","author":"F Asamoah","year":"2017","unstructured":"Asamoah F, Kakourou A, Dhami S, Lau S, Agache I, Muraro A, et al. Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. Clin Transl Allergy. 2017;7:25.","journal-title":"Clin Transl Allergy"},{"key":"1224_CR61","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.anai.2024.06.016","volume":"134","author":"B Olivieri","year":"2025","unstructured":"Olivieri B, G\u00fcnayd\u0131n FE, Corren J, Senna G, Durham SR. The combination of allergen immunotherapy and biologics for inhalant allergies: exploring the synergy. Ann Allergy Asthma Immunol. 2025;134:385\u201395.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR62","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jaip.2025.05.003","volume":"13","author":"D Larenas-Linnemann","year":"2025","unstructured":"Larenas-Linnemann D, Diamant Z, Jesenak M, Navarrete-Rodr\u00edguez EM, Kappen J, Porsbjerg C. Combination of allergen-specific immunotherapy with biologics in severe asthma: counterintuitive or rational? J Allergy Clin Immunol Pract. 2025;13:1581\u201396.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR63","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","volume":"117","author":"TB Casale","year":"2006","unstructured":"Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134\u201340.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR64","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jaci.2009.11.022","volume":"125","author":"M Massanari","year":"2010","unstructured":"Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125:383\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR65","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/alr.23268","volume":"14","author":"Y-Y Zhang","year":"2024","unstructured":"Zhang Y-Y, Zhang M, Zhang J-Q, Li Q-Q, Lu M-P, Cheng L. Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: a meta-analysis of randomized controlled trials. Int Forum Allergy Rhinol. 2024;14:794\u2013806.","journal-title":"Int Forum Allergy Rhinol"},{"key":"1224_CR66","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2147\/JAA.S318892","volume":"14","author":"J Corren","year":"2021","unstructured":"Corren J, Saini SS, Gagnon R, Moss MH, Sussman G, Jacobs J, et al. Short-Term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: A randomized trial. J Asthma Allergy. 2021;14:1045\u201363.","journal-title":"J Asthma Allergy"},{"key":"1224_CR67","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","volume":"151","author":"J Corren","year":"2023","unstructured":"Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, et al. Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial. J Allergy Clin Immunol. 2023;151:192\u2013201.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR68","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","volume":"63","author":"K Kontou-Fili","year":"2008","unstructured":"Kontou-Fili K. High Omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy. 2008;63:376\u20138.","journal-title":"Allergy"},{"key":"1224_CR69","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/j.1398-9995.2009.02045.x","volume":"64","author":"K Kontou-Fili","year":"2009","unstructured":"Kontou-Fili K, Filis CI. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy. 2009;64:1384\u20135.","journal-title":"Allergy"},{"key":"1224_CR70","first-page":"687","volume":"1","author":"EN da Silva","year":"2013","unstructured":"da Silva EN, Randall KL. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. The Journal of Allergy and Clinical Immunology: In Practice. 2013;1:687\u20138.","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"1224_CR71","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jaip.2015.03.015","volume":"3","author":"MC Castells","year":"2015","unstructured":"Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract. 2015;3:350\u20135.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR72","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jaip.2019.10.022","volume":"8","author":"M Giannetti","year":"2020","unstructured":"Giannetti M, Silver J, Hufdhi R, Castells M. One-day Ultrarush desensitization for hymenoptera venom anaphylaxis in patients with and without mast cell disorders with adjuvant Omalizumab. J Allergy Clin Immunol Pract. 2020;8:1431\u2013e14353.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR73","doi-asserted-by":"publisher","first-page":"128","DOI":"10.5414\/ALX02196E","volume":"5","author":"A G\u00fclsen","year":"2021","unstructured":"G\u00fclsen A, Ru\u00ebff F, Jappe U. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis. Allergol Select. 2021;5:128\u201332.","journal-title":"Allergol Select"},{"key":"1224_CR74","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1398-9995.2007.01388.x","volume":"62","author":"J Schulze","year":"2007","unstructured":"Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by Omalizumab. Allergy. 2007;62:963\u20134.","journal-title":"Allergy"},{"key":"1224_CR75","first-page":"225","volume":"19","author":"C Galera","year":"2009","unstructured":"Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol. 2009;19:225\u20139.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1224_CR76","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/039463201402700114","volume":"27","author":"K Palgan","year":"2014","unstructured":"Palgan K, Bartuzi Z, Gotz-Zbikowska M. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a Wasp sting. Int J Immunopathol Pharmacol. 2014;27:109\u201312.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1224_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12948-016-0051-2","volume":"14","author":"E Boni","year":"2016","unstructured":"Boni E, Incorvaia C, Mauro M. Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy. 2016;14:14.","journal-title":"Clin Mol Allergy"},{"key":"1224_CR78","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1111\/cea.12997","volume":"47","author":"E Stretz","year":"2017","unstructured":"Stretz E, Oppel EM, R\u00e4wer HC, Chatelain R, Mastnik S, Przybilla B, et al. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose. Clin Exp Allergy. 2017;47:1631\u20139.","journal-title":"Clin Exp Allergy"},{"key":"1224_CR79","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/all.13262","volume":"73","author":"GJ Sturm","year":"2018","unstructured":"Sturm GJ, Varga EM, Roberts G, Mosbech H, Bil\u00f2 MB, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy. 2018;73:744\u201364.","journal-title":"Allergy"},{"key":"1224_CR80","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.iac.2021.12.004","volume":"42","author":"BC Yang","year":"2022","unstructured":"Yang BC, Castells MC. The who, what, where, when, why, and how of drug desensitization. Immunol Allergy Clin North Am. 2022;42:403\u201320.","journal-title":"Immunol Allergy Clin North Am"},{"key":"1224_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11882-022-01052-z","volume":"23","author":"BC Yang","year":"2023","unstructured":"Yang BC, Castells MC. Utilizing biologics in drug desensitization. Curr Allergy Asthma Rep. 2023;23:1\u201311.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1224_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12086","volume":"11","author":"RS Bumbacea","year":"2021","unstructured":"Bumbacea RS, Ali S, Corcea SL, Spiru L, Nitipir C, Strambu V, et al. Omalizumab for successful chemotherapy desensitisation: what we know so far. Clin Transl Allergy. 2021;11:e12086.","journal-title":"Clin Transl Allergy"},{"key":"1224_CR83","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/ACI.0000000000000648","volume":"20","author":"J Fernandez","year":"2020","unstructured":"Fernandez J, Ruano-Zaragoza M, Blanca-Lopez N. Omalizumab and other biologics in drug desensitization. Curr Opin Allergy Clin Immunol. 2020;20:333\u20137.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1224_CR84","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jaip.2025.02.028","volume":"13","author":"J Oh","year":"2025","unstructured":"Oh J, Vasquez EC, Alvarez-Arango S, Ramesh M, Castells MC. Insulin allergy: the allergist\u2019s updated approach to evaluation and management. J Allergy Clin Immunol Pract. 2025;13:990\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR85","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.jaci.2007.07.037","volume":"120","author":"V Matheu","year":"2007","unstructured":"Matheu V, Franco A, Perez E, Hern\u00e1ndez M, Barrios Y. Omalizumab for drug allergy. J Allergy Clin Immunol. 2007;120:1471\u20132. author reply 1472.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR86","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMc0808282","volume":"360","author":"PFK Yong","year":"2009","unstructured":"Yong PFK, Malik R, Arif S, Peakman M, Amiel S, Ibrahim MAA, et al. Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med. 2009;360:1045\u20137.","journal-title":"N Engl J Med"},{"key":"1224_CR87","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13601-018-0223-x","volume":"8","author":"MB Haastrup","year":"2018","unstructured":"Haastrup MB, Henriksen JE, Mortz CG, Bindslev-Jensen C. Insulin allergy can be successfully managed by a systematic approach. Clin Transl Allergy. 2018;8:35.","journal-title":"Clin Transl Allergy"},{"key":"1224_CR88","doi-asserted-by":"publisher","first-page":"293","DOI":"10.18176\/jiaci.0496","volume":"30","author":"J Penella","year":"2020","unstructured":"Penella J, Quan P, Carvallo A, Chopitea A, Sala P, Del Garc\u00eda MA, et al. Successful desensitization to oxaliplatin after a single initial dose of Omalizumab in a patient with elevated Ige levels. J Investig Allergol Clin Immunol. 2020;30:293\u20135.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1224_CR89","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18176\/jiaci.0326","volume":"29","author":"A Prieto-Garc\u00eda","year":"2019","unstructured":"Prieto-Garc\u00eda A, Noguerado B, Rojas P, Torrado I, Rodr\u00edguez-Fern\u00e1ndez A, Tornero P. Unexpected anaphylaxis after completing a desensitization protocol to oxaliplatin: successful adjuvant use of Omalizumab. J Investig Allergol Clin Immunol. 2019;29:53\u20135.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1224_CR90","doi-asserted-by":"publisher","first-page":"298","DOI":"10.18176\/jiaci.0499","volume":"30","author":"L S\u00e1nchez-Morillas","year":"2020","unstructured":"S\u00e1nchez-Morillas L, Casado Herr\u00e1ez A, Rubio-Perez M, Robledo Echarren T, Gonz\u00e1lez Guti\u00e9rrez ML, Cimarra M, et al. Usefulness of omalizumab in rapid drug desensitization in patients with severe anaphylaxis induced by carboplatin: open questions. J Investig Allergol Clin Immunol. 2020;30:298\u2013300.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1224_CR91","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaip.2013.08.009","volume":"2","author":"S Ojaimi","year":"2014","unstructured":"Ojaimi S, Harnett PR, Fulcher DA. Successful carboplatin desensitization by using Omalizumab and paradoxical diminution of total IgE levels. J Allergy Clin Immunol Pract. 2014;2:105\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-020-0309-0","volume":"10","author":"HNG Oude Elberink","year":"2020","unstructured":"Oude Elberink HNG, Jalving M, van de Dijkstra H. Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study. Clin Transl Allergy. 2020;10:5.","journal-title":"Clin Transl Allergy"},{"key":"1224_CR93","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13783","volume":"33","author":"HB Gemici Karaaslan","year":"2022","unstructured":"Gemici Karaaslan HB, Karabag Yilmaz E, Gulmez R, Canpolat N, Kiykim A, Cokugras HC. Omalizumab may facilitate drug desensitization in patients failing standard protocols. Pediatr Allergy Immunol. 2022;33:e13783.","journal-title":"Pediatr Allergy Immunol"},{"key":"1224_CR94","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaip.2023.09.019","volume":"12","author":"TM Laidlaw","year":"2024","unstructured":"Laidlaw TM, White AA. Should biologics be used before aspirin desensitization in aspirin-exacerbated respiratory disease? J Allergy Clin Immunol Pract. 2024;12:79\u201384.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR95","doi-asserted-by":"publisher","unstructured":"Cockcroft DW. NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance. Eur Respir J. 2023;61(3):2202467. https:\/\/doi.org\/10.1183\/13993003.02467-2022","DOI":"10.1183\/13993003.02467-2022"},{"key":"1224_CR96","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaci.2017.05.006","volume":"141","author":"J Waldram","year":"2018","unstructured":"Waldram J, Walters K, Simon R, Woessner K, Waalen J, White A. Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single-center study. J Allergy Clin Immunol. 2018;141:250\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR97","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","volume":"121","author":"DM Lang","year":"2018","unstructured":"Lang DM, Aronica MA, Maierson ES, Wang X-F, Vasas DC, Hazen SL. Omalizumab can inhibit respiratory reaction during aspirin desensitization. Ann Allergy Asthma Immunol. 2018;121:98\u2013104.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR98","doi-asserted-by":"publisher","unstructured":"Schneider S, Poglitsch K, Morgenstern C, Quint T, Gangl K, Sinz C, et al. Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease. Eur Respir J. 2023;61(3):2201335. https:\/\/doi.org\/10.1183\/13993003.01335-2022","DOI":"10.1183\/13993003.01335-2022"},{"key":"1224_CR99","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.jaip.2023.04.033","volume":"11","author":"J S\u00e1nchez","year":"2023","unstructured":"S\u00e1nchez J, Garc\u00eda E, Lopez J-F, Calle A, Buendia J-A. Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: a randomized comparative trial. J Allergy Clin Immunol Pract. 2023;11:2172\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR100","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaip.2014.02.012","volume":"2","author":"PA Greenberger","year":"2014","unstructured":"Greenberger PA, Lieberman P. Idiopathic anaphylaxis. J Allergy Clin Immunol Pract. 2014;2:243\u201350. quiz 251.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR101","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/0003-4819-114-2-133","volume":"114","author":"S Wong","year":"1991","unstructured":"Wong S, Yarnold PR, Yango C, Patterson R, Harris KE. Outcome of prophylactic therapy for idiopathic anaphylaxis. Ann Intern Med. 1991;114:133\u20136.","journal-title":"Ann Intern Med"},{"key":"1224_CR102","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39:2216\u201329.","journal-title":"Clin Ther"},{"key":"1224_CR103","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.anai.2019.08.024","volume":"124","author":"MC Carter","year":"2020","unstructured":"Carter MC, Akin C, Castells MC, Scott EP, Lieberman P. Idiopathic anaphylaxis yardstick: practical recommendations for clinical practice. Ann Allergy Asthma Immunol. 2020;124:16\u201327.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR104","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1081-1206(10)60091-9","volume":"102","author":"P Warrier","year":"2009","unstructured":"Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol. 2009;102:257\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR105","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S1081-1206(10)60296-7","volume":"101","author":"JD Jones","year":"2008","unstructured":"Jones JD, Marney SR, Fahrenholz JM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol. 2008;101:550\u20131.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR106","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1346-8138.2012.01520.x","volume":"39","author":"M Demirt\u00fcrk","year":"2012","unstructured":"Demirt\u00fcrk M, Gelincik A, Colako\u011flu B, Dal M, B\u00fcy\u00fck\u00f6zt\u00fcrk S. Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol. 2012;39:552\u20134.","journal-title":"J Dermatol"},{"key":"1224_CR107","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5152\/TurkPediatriArs.2017.2262","volume":"52","author":"\u00d6 \u00d6zdemir","year":"2017","unstructured":"\u00d6zdemir \u00d6, Bozkurt HB, Elmas B. Omalizumab\u2019s role in the treatment of steroid dependent malignant idiopathic anaphylaxis. Turk Pediatri Ars. 2017;52:105\u20137.","journal-title":"Turk Pediatri Ars"},{"key":"1224_CR108","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.anai.2019.09.020","volume":"123","author":"MC Sanchez-Valenzuela","year":"2019","unstructured":"Sanchez-Valenzuela MC, Garcia-Saucedo JC, Motoa G, Carrillo-Martin I, Gonzalez-Estrada A. Treatment of idiopathic anaphylaxis with omalizumab. Ann Allergy Asthma Immunol. 2019;123:612\u20133.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR109","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15165","volume":"34","author":"GK Singh","year":"2021","unstructured":"Singh GK. Omalizumab, a savior in long term prevention of idiopathic anaphylaxis with urticaria: a case series. Dermatol Ther. 2021;34:e15165.","journal-title":"Dermatol Ther"},{"key":"1224_CR110","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.anai.2021.06.017","volume":"127","author":"LW Kaminsky","year":"2021","unstructured":"Kaminsky LW, Aukstuolis K, Petroni DH, Al-Shaikhly T. Use of omalizumab for management of idiopathic anaphylaxis: a systematic review and retrospective case series. Ann Allergy Asthma Immunol. 2021;127:481\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR111","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jaci.2020.11.005","volume":"147","author":"MC Carter","year":"2021","unstructured":"Carter MC, Maric I, Brittain EH, Bai Y, Lumbard K, Bolan H, et al. A randomized double-blind, placebo-controlled study of Omalizumab for idiopathic anaphylaxis. J Allergy Clin Immunol. 2021;147:1004\u2013e10102.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR112","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S1081-1206(10)62547-1","volume":"85","author":"LC Grammer","year":"2000","unstructured":"Grammer LC, Shaughnessy MA, Harris KE, Goolsby CL. Lymphocyte subsets and activation markers in patients with acute episodes of idiopathic anaphylaxis. Ann Allergy Asthma Immunol. 2000;85:368\u201371.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR113","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jaci.2014.05.032","volume":"134","author":"A Borzutzky","year":"2014","unstructured":"Borzutzky A, Morales PS, Mezzano V, Nussbaum S, Burks AW. Induction of remission of idiopathic anaphylaxis with rituximab. J Allergy Clin Immunol. 2014;134:981\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR114","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jaci.2008.11.043","volume":"123","author":"PD Arkwright","year":"2009","unstructured":"Arkwright PD. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. J Allergy Clin Immunol. 2009;123:510\u20131. author reply 511.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR115","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jaci.2011.08.023","volume":"128","author":"SD Chakravarty","year":"2011","unstructured":"Chakravarty SD, Yee AF, Paget SA. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. J Allergy Clin Immunol. 2011;128:1354\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR116","doi-asserted-by":"publisher","unstructured":"Gowthaman U, Chen JS, Zhang B, Flynn WF, Lu Y, Song W, et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science. 2019;365(6456):eaaw6433. https:\/\/doi.org\/10.1126\/science.aaw6433","DOI":"10.1126\/science.aaw6433"},{"key":"1224_CR117","doi-asserted-by":"publisher","unstructured":"Nguyen SMT, Rupprecht CP, Haque A, Pattanaik D, Yusin J, Krishnaswamy G. Mechanisms governing anaphylaxis: inflammatory cells, mediators, endothelial gap junctions and beyond. Int J Mol Sci. 2021;22(15):7785. https:\/\/doi.org\/10.3390\/ijms22157785","DOI":"10.3390\/ijms22157785"},{"key":"1224_CR118","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jaci.2020.11.042","volume":"147","author":"K Bruton","year":"2021","unstructured":"Bruton K, Spill P, Vohra S, Baribeau O, Manzoor S, Gadkar S, et al. Interrupting reactivation of immunologic memory diverts the allergic response and prevents anaphylaxis. J Allergy Clin Immunol. 2021;147:1381\u201392.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR119","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41590-025-02077-y","volume":"26","author":"P Chandrakar","year":"2025","unstructured":"Chandrakar P, Nelson CS, Podest\u00e0 MA, Cavazzoni CB, Gempler M, Lee J-M, et al. Progressively differentiated TFH13 cells are stabilized by JunB to mediate allergen germinal center responses. Nat Immunol. 2025;26:473\u201383.","journal-title":"Nat Immunol"},{"key":"1224_CR120","doi-asserted-by":"publisher","first-page":"230","DOI":"10.18176\/jiaci.0840","volume":"33","author":"T Otani","year":"2023","unstructured":"Otani T, Iwamoto H, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, et al. Effect of dupilumab in a patient with severe asthma complicated with recurrent anaphylaxis: a case report. J Investig Allergol Clin Immunol. 2023;33:230\u20132.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1224_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-023-00838-8","volume":"19","author":"E Pepper","year":"2023","unstructured":"Pepper E, Pittman L. Treatment of idiopathic anaphylaxis with dupilumab: a case report. Allergy Asthma Clin Immunol. 2023;19:82.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1224_CR122","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.iac.2023.04.010","volume":"43","author":"T Gulen","year":"2023","unstructured":"Gulen T. Management of mediator symptoms, allergy, and anaphylaxis in mastocytosis. Immunol Allergy Clin North Am. 2023;43:681\u201398.","journal-title":"Immunol Allergy Clin North Am"},{"key":"1224_CR123","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","volume":"63","author":"K Brockow","year":"2008","unstructured":"Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226\u201332.","journal-title":"Allergy"},{"key":"1224_CR124","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cea.12225","volume":"44","author":"T G\u00fclen","year":"2014","unstructured":"G\u00fclen T, H\u00e4gglund H, Dahl\u00e9n B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clin Exp Allergy. 2014;44:121\u20139.","journal-title":"Clin Exp Allergy"},{"key":"1224_CR125","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000096442","volume":"142","author":"K Sonneck","year":"2007","unstructured":"Sonneck K, Florian S, M\u00fcllauer L, Wimazal F, F\u00f6dinger M, Sperr WR, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol. 2007;142:158\u201364.","journal-title":"Int Arch Allergy Immunol"},{"key":"1224_CR126","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","volume":"110","author":"C Akin","year":"2007","unstructured":"Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with idiopathic anaphylaxis. Blood. 2007;110:2331\u20133.","journal-title":"Blood"},{"key":"1224_CR127","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cea.12369","volume":"44","author":"T G\u00fclen","year":"2014","unstructured":"G\u00fclen T, H\u00e4gglund H, Sander B, Dahl\u00e9n B, Nilsson G. The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy. 2014;44:1179\u201387.","journal-title":"Clin Exp Allergy"},{"key":"1224_CR128","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","volume":"119","author":"MC Carter","year":"2007","unstructured":"Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007;119:1550\u20131.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR129","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","volume":"65","author":"JA Douglass","year":"2010","unstructured":"Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O\u2019Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy. 2010;65:926\u20137.","journal-title":"Allergy"},{"key":"1224_CR130","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jaci.2010.05.043","volume":"126","author":"TJ Pitt","year":"2010","unstructured":"Pitt TJ, Cisneros N, Kalicinsky C, Becker AB. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol. 2010;126:415\u20136. author reply 416.","journal-title":"J Allergy Clin Immunol"},{"key":"1224_CR131","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2340\/00015555-1687","volume":"94","author":"L Kibsgaard","year":"2014","unstructured":"Kibsgaard L, Skjold T, Deleuran M, Vestergaard C. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. Acta Derm Venereol. 2014;94:363\u20134.","journal-title":"Acta Derm Venereol"},{"key":"1224_CR132","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","volume":"108","author":"MC Bell","year":"2012","unstructured":"Bell MC, Jackson DJ. Prevention of anaphylaxis related to mast cell activation syndrome with Omalizumab. Ann Allergy Asthma Immunol. 2012;108:383\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR133","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","volume":"7","author":"R Lemal","year":"2019","unstructured":"Lemal R, Fouquet G, Terriou L, Vaes M, Livideanu CB, Frenzel L, et al. Omalizumab therapy for mast Cell-Mediator symptoms in patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract. 2019;7:2387\u2013e23953.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR134","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cea.13592","volume":"50","author":"F Jendoubi","year":"2020","unstructured":"Jendoubi F, Gaudenzio N, Gallini A, Negretto M, Paul C, Bulai Livideanu C. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50:654\u201361.","journal-title":"Clin Exp Allergy"},{"key":"1224_CR135","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.jaip.2023.04.008","volume":"11","author":"JS McComish","year":"2023","unstructured":"McComish JS, Slade CA, Buizen L, Paul SK, Chatelier JW, Unglik G, et al. Randomized controlled trial of Omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM). J Allergy Clin Immunol Pract. 2023;11:2248\u2013e22503.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1224_CR136","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ng.3696","volume":"48","author":"JJ Lyons","year":"2016","unstructured":"Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48:1564\u20139.","journal-title":"Nat Genet"},{"key":"1224_CR137","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.anai.2021.01.016","volume":"126","author":"MP Giannetti","year":"2021","unstructured":"Giannetti MP, Weller E, Bormans C, Novak P, Hamilton MJ, Castells M. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis. Ann Allergy Asthma Immunol. 2021;126:655\u201360.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR138","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1159\/000538046","volume":"185","author":"M Ko\u0161nik","year":"2024","unstructured":"Ko\u0161nik M, Zugan L, Rijavec M. Prevention of anaphylaxis episodes in idiopathic anaphylaxis by omalizumab. Int Arch Allergy Immunol. 2024;185:761\u20136.","journal-title":"Int Arch Allergy Immunol"},{"key":"1224_CR139","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.anai.2019.09.026","volume":"124","author":"LB Mendoza Alvarez","year":"2020","unstructured":"Mendoza Alvarez LB, Barker R, Nelson C, DiMaggio T, Stone KD, Milner JD, et al. Clinical response to Omalizumab in patients with hereditary \u03b1-tryptasemia. Ann Allergy Asthma Immunol. 2020;124:99\u2013e1001.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1224_CR140","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11882-023-01123-9","volume":"24","author":"V Sabato","year":"2024","unstructured":"Sabato V, Beyens M, Toscano A, Van Gasse A, Ebo DG. Mast cell-targeting therapies in mast cell activation syndromes. Curr Allergy Asthma Rep. 2024;24:63\u201371.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1224_CR141","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/13543784.2023.2277385","volume":"32","author":"B Wedi","year":"2023","unstructured":"Wedi B. Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development. Expert Opin Investig Drugs. 2023;32:1043\u201354.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-025-01224-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-025-01224-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-025-01224-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:05:13Z","timestamp":1759993513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-025-01224-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1007\/s11882-025-01224-7","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"type":"print","value":"1529-7322"},{"type":"electronic","value":"1534-6315"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Iweala reports grants from NIH NIAID K08 AI141691, Clinical Trial, Site PI for Telios Pharma, receives personal fees from Blueprint Medicines\/Sanofi, Allakos, Inc., and Techspert, Inc., and is a co-author on an industry-sponsored manuscript from Genentech, during the conduct of the study. Dr. Song, Dr. Sood, Dr. Schworer, and Dr. Kwan declare that they do not have any conflict of interest with regard to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}